SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Granules India informs about press release

08 Jan 2026 Evaluate
Granules India has informed that it enclosed the press release given by the Company titled ‘Granules Pharmaceuticals, Inc. Receives FDA Tentative Approval with 180-Day Exclusivity for Generic Amphetamine Extended-Release Tablets (gDYANAVEL XR)’.

The above information is a part of company’s filings submitted to BSE.

Granules India Share Price

781.70 40.55 (5.47%)
18-Jun-2026 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1826.95
Dr. Reddys Lab 1271.00
Cipla 1358.90
Zydus Lifesciences 1070.95
Lupin 2331.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: